Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection. - Wikidata - wikimedia - TriplyDB

Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection.

Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection.

http://www.wikidata.org/entity/Q37126749

about

Ribavirin plus interferon versus interferon for chronic hepatitis C Treatment of Hepatitis C Virus Infection in Children Less than 12 Years of Age in Developing Countries Impact of Hepatitis C Virus Infection on Children and Their Caregivers: Quality of Life, Cognitive, and Emotional Outcomes Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C: a retrospective study.The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children Treatment and follow up of children with chronic hepatitis C in Albania.Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial.Recruitment and retention strategies in a clinical trial for children with chronic hepatitis C infection Autoantibodies and autoimmune disease during treatment of children with chronic hepatitis C.Managing pediatric hepatitis C: current and emerging treatment options.Treatment of hepatitis C in children.

P2860

Q24240879-7E4224AE-DF3F-4149-B43E-C1BEFAE2BD09 Q26781890-AC9B12B9-7D15-4EEB-B3F0-8A1681562B80 Q27487975-1CF703B7-A1CA-48DA-B06A-82107FAC7F3C Q33862153-CF8C8539-59BA-4087-BE73-22C3AA7A6E9B Q34588247-94C59A15-FF95-432D-8026-75728012CF68 Q34861058-1264A5E2-4CF4-4769-BC33-75A45A12864B Q35735622-A73909EB-B0E6-4150-B752-EF756B2F92BB Q36055220-0DB67A56-5882-49DE-92A3-CB3D013067AE Q36518161-2BF39A9A-2CAE-4B6D-8E64-A0F6D257F6E2 Q36641415-1F48491F-54D8-41C1-A7C7-567CFE3D2C48 Q37316248-9F3B84BD-BA3B-43A8-AD32-F1FCE2C8E467 Q50560594-146E1683-69FF-465A-B71F-CBCBF57B7B5C

P2860

Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection.

http://www.wikidata.org/entity/Q37126749

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Design of the PEDS-C trial: pe ...... c hepatitis C viral infection.

@en

Design of the PEDS-C trial: pe ...... c hepatitis C viral infection.

@nl

type

label

Design of the PEDS-C trial: pe ...... c hepatitis C viral infection.

@en

Design of the PEDS-C trial: pe ...... c hepatitis C viral infection.

@nl

prefLabel

Design of the PEDS-C trial: pe ...... c hepatitis C viral infection.

@en

Design of the PEDS-C trial: pe ...... c hepatitis C viral infection.

@nl

P1433

Q37126749-508AF476-3ACC-46F5-9C67-F70D3AFD828E

P1476

Q37126749-D7654311-4592-42FC-9607-8A81034E00CE

P2093

Q37126749-21ABCF61-0896-4B18-8810-B51C84C8B27B

Q37126749-24296695-D967-4367-B93F-0EDA4226D05D

Q37126749-4C553114-4A21-4565-AB8E-71092C365EEE

Q37126749-51763133-B573-4782-B376-34219DBB2648

Q37126749-6B2052B2-34BC-499C-8023-D874943708D4

Q37126749-8070D636-7F16-45EF-88A0-BF744638C8E0

Q37126749-E5291A98-8C47-4185-972D-B05D5E5E06E0

P2860

Q37126749-0395B735-4F31-46F9-8D90-1BB27D3AA8E4

Q37126749-0BFE922C-3547-4247-BE30-0E12A686607F

Q37126749-10C4A857-D91D-469F-9760-8DF432143818

Q37126749-1A0ACD5E-3593-4B79-B96B-BEA1C0E511E6

Q37126749-2C484EAE-A791-4092-835B-468217E6FE78

Q37126749-2CEB6DEE-768F-4767-B2F3-92A9997B38A7

Q37126749-50BF90C7-FCE9-46CF-B658-02BBE5F928F2

Q37126749-5CAC9128-2B7B-447E-BE8B-0E4F15EB4261

Q37126749-653002B2-032E-403A-B8B3-838438AA66BD

Q37126749-663E1CA8-8281-4156-9568-CC7370FEEDAF

P304

Q37126749-31F84D86-AFEE-43AD-9F36-E505C1120A2A

P31

Q37126749-FC85ECEE-0189-478E-8680-85A57DD9E3EC

P356

Q37126749-676D5D93-2B8F-4DF9-9DBC-C2FE0B698AED

P433

Q37126749-BDCB8291-988C-4D7B-A07B-6597DE23A1CD

P478

Q37126749-941EDBBD-C848-49F0-A90A-111F79E30548

P50

Q37126749-202D0FFB-7D49-4C8A-B662-2ED28347B92E

P577

Q37126749-BD966A26-15C9-4C0C-AF5D-10B1AF9BEF99

P698

Q37126749-5FD2BEF4-A8AB-4357-92FA-606CDF309E4F

P932

Q37126749-DC9A3ED9-B433-4DD7-A8B2-0A781450E20B

P356

1740774507085445

P1433

Clinical Trials

P1476

Design of the PEDS-C trial: pe ...... c hepatitis C viral infection.

@en

P2093

James R Rodrigue

http://www.w3.org/2001/XMLSchema#string

John Shepherd

http://www.w3.org/2001/XMLSchema#string

Karen F Murray

http://www.w3.org/2001/XMLSchema#string

Kathleen B Schwarz

http://www.w3.org/2001/XMLSchema#string

PEDS-C Clinical Research Network

http://www.w3.org/2001/XMLSchema#string

Patricia R Robuck

http://www.w3.org/2001/XMLSchema#string

Regino P González-Peralta

http://www.w3.org/2001/XMLSchema#string

P2860

Statistical methods for assessing agreement between two methods of clinical measurement

Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

A multiple testing procedure for clinical trials

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

Mood disorders associated with interferon treatment: theoretical and practical considerations.

An analysis of published trials of interferon monotherapy in children with chronic hepatitis C.

Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C.

P304

661-673

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1740774507085445

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18042575

http://www.w3.org/2001/XMLSchema#string

P932

3755272

http://www.w3.org/2001/XMLSchema#string